Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

hsa-miR-23a-3p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

Clearance sale RDM0009H 96 wells (1 kit)
PubMed Product Details
Technical Data


miREIA – miRNA enzyme immunoassay


Whole blood

Sample Requirements

10 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

12.5 – 0.39 amol/μl

Limit of Detection

0.13 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 5.1%

Inter-assay (Run-to-Run)

n = 5,
CV = 6.3%

Spiking Recovery


Dilution Linearity



Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.


Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.

Product Manual: miREIA - microRNA enzyme immunoassay



Exact inter-species homology was found for example for:

Bornean orangutan
Brown anole
Brown bat
Carolina anole
Chinese hamster
Geoffroy's spider monkey
Green spotted puffer
Japanese rice fish
King cobra
Ring-tailed lemur
Western gorilla
White-lipped tamarin
Wild boar


  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-23a-3p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic



MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in the pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

hsa-miR-23a-3p is located in the miR-23a~27a~24-2 cluster. miR-23a-3p has been reported to be upregulated and have a promoting role in several cancer types via targeting various tumor-suppressor genes. It was also observed that up-regulated expression of miR-23a-3p inhibits apoptosis, promotes autophagy and enhances cell colony formation, migration and invasion. Several lines of evidence suggest that dysregulation of miR-23a-3p plays a role in chemoresistance in various types of cancer.

It was also reported that circulating miR-23a-3p may be involved in postoperative atrial fibrillation development. Decreasedevel of miR-23a-3p was observed in serum of women with polycystic ovary syndrome and could serve as an indicator of this syndrome.

Moreover, it has been shown that miR-23a-3p plays important roles in myogenesis of skeletal muscle, fiber type determination or exercise adaptation. Overexpression of miR-23-3p could suppress muscle atrophy both in vitro and in vivo.

Summary References (12)

References to miR-23a-3p

  • Chhabra, Ravindresh, Richa Dubey, and Neeru Saini. "Cooperative and individualistic functions of the microRNAs in the miR-23a~ 27a~ 24-2 cluster and its implication in human diseases." Molecular cancer 9.1 (2010): 232.
  • Mi, Shuangli, et al. "MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia." Proceedings of the National Academy of Sciences104.50 (2007): 19971-19976.
  • Li, Xiaoni, et al. "c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2." Journal of Biological Chemistry 288.25 (2013): 18121-18133.
  • Ma, Gang, et al. "Upregulation of microRNA-23a/b promotes tumor progression and confers poor prognosis in patients with gastric cancer." International journal of clinical and experimental pathology 7.12 (2014): 8833.
  • Tian, K., R. Di, and L. Wang. "MicroRNA-23a enhances migration and invasion through PTEN in osteosarcoma." Cancer gene therapy 22.7 (2015): 351-359.
  • Chen, Ping, et al. "MiR-23a modulates X-linked inhibitor of apoptosis-mediated autophagy in human luminal breast cancer cell lines." Oncotarget 8.46 (2017): 80709.
  • Yu, Zhi-wei, et al. "MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines." Oral oncology 46.4 (2010): 317-322.
  • Jin, Ai-Hong, and Zhao-Lian Wei. "Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression." International journal of clinical and experimental medicine 8.8 (2015): 13329.
  • Feldman, Andre, et al. "Analysis of Circulating miR‐1, miR‐23a, and miR‐26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery." Annals of human genetics 81.3 (2017): 99-105.
  • Xiong, Weixi, et al. "Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population." Journal of ovarian research 10.1 (2017): 10.
  • Nie, Mao, et al. "Noncoding RNAs, emerging regulators of skeletal muscle development and diseases." BioMed research international 2015 (2015).
  • Wang, Fei, et al. "Serum miRNAs miR-23a, 206, and 499 as Potential Biomarkers for Skeletal Muscle Atrophy." BioMed Research International 2017 (2017).
Related Products Docs